Science Explorer Back to mapMap
Discussion
Company · Solna · Sweden

Empros Pharma (Sweden)

emprospharma.comROR OpenAlex
Research works
2
▼ 39% vs 2018-21
Citations
34
14.0 per fractional work
Top-10% rate
10.9%
all institutions 10.0%
Open access
66%
world 40%
Empros Pharma (Sweden)

Not ranked overall: Empros Pharma (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Empros Pharma (Sweden) work in?

In all years, 84% of research at Empros Pharma (Sweden) is in Health Sciences, 12% in Life Sciences. Its largest fields are Medicine (72%), Biochemistry, Genetics and Molecular Biology (12%), Nursing (12%). It does 1.4× the world's share of Health Sciences.

Health Sciences: 2 fractional works · 84.0% of its workMedicine: 2 fractional works · 72.0% of its workNursing: 0 fractional works · 12.0% of its workLife Sciences: 0 fractional works · 12.0% of its workBiochemistry, Genetics and Molecular Biology: 0 fractional works · 12.0% of its workPhysical Sciences: 0 fractional works · 4.0% of its workChemistry: 0 fractional works · 4.0% of its workALL ITS WORKEmpros Pharma(Sweden)2fractional works, all years
Life Sciences12%Physical Sciences4%Health Sciences84%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 4 fields, with their numbers
    1. Medicine272.0%
    2. Nursing012.0%
    1. Biochemistry, Genetics and Molecular Biology012.0%
    1. Chemistry04.0%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Empros Pharma (Sweden)?

The most cited paper from Empros Pharma (Sweden) is "Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity" (Ulf C. Holmbäck, Anders H. Forslund, Stefan Grudén et al., 2020), with 35 citations. Next come "Effects of a novel weight‐loss combination product containing orlistat and acarbose on obesity: A randomized, placebo‐controlled trial" (25) and "Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study" (12).

Most cited papers
#PaperReleasedCitations
1 Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity Ulf C. Holmbäck, Anders H. Forslund, Stefan Grudén et al. · Obesity Science & Practice Open access 22 Jan 2020 35
2 Effects of a novel weight‐loss combination product containing orlistat and acarbose on obesity: A randomized, placebo‐controlled trial Ulf C. Holmbäck, Stefan Grudén, Helena Litorp et al. · Obesity Open access 19 Sep 2022 25
3 Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study Eva Lesén, Daniel Granfeldt, Anthony Berthon et al. · Journal of Cancer Open access 2019 12
4 Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose Stefan Grudén, Anders H. Forslund, Göran Alderborn et al. · Clinical Pharmacology in Drug Development Open access 13 Feb 2021 10
5 The Supportive Effect of Acarbose to Orlistat in Weight Management—A Randomized, Double‐Blind, Multiarm Phase 2 Trial Ulf C. Holmbäck, Stefan Grudén, Sandra Kuusk et al. · Obesity Open access 6 Aug 2025 2
All 8 most cited papers, with filters and sorting

Which research topics does Empros Pharma (Sweden) publish most on?

By volume in 2022-now: Pharmacology and Obesity Treatment, Bariatric Surgery and Outcomes, Nuts composition and effects and Hormonal and reproductive studies.

Pharmacology and Obesity…0Pharmacology and Obesity Treatment: 0 fractional worksBariatric Surgery and Ou…0Bariatric Surgery and Outcomes: 0 fractional worksNuts composition and eff…0Nuts composition and effects: 0 fractional worksHormonal and reproductiv…0Hormonal and reproductive studies: 0 fractional worksMuscle metabolism and nu…0Muscle metabolism and nutrition: 0 fractional worksPlant-Derived Bioactive …0Plant-Derived Bioactive Compounds: 0 fractional works
PharmacologySurgeryNutrition and DieteticsEndocrinology, Diabetes and Metabolism2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Pharmacology and Obesity Treatment Pharmacology 0 works
  2. 2 Bariatric Surgery and Outcomes Surgery 0 works
  3. 3 Nuts composition and effects Nutrition and Dietetics 0 works
  4. 4 Hormonal and reproductive studies Endocrinology, Diabetes and Metabolism 0 works
  5. 5 Muscle metabolism and nutrition Cell Biology 0 works
  6. 6 Plant-Derived Bioactive Compounds Organic Chemistry 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available65.5%not open34.5%

World: 40% of research is openly available.

How has Empros Pharma (Sweden)'s research output changed?

Output in 2022-2025 was 39% lower than in 2018-2021.

still counting20202025

Other research institutions in Solna

All research institutions in Solna

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Empros Pharma (Sweden). Posts are plain text and can be reported.